MedTrace Logo

Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

NCT00923884 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 546

Last updated 2019-10-09

No results posted yet for this study

Summary

Background:

* The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer.

Objectives:

* To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer.
* To establish a repository of genetic information for future studies of these differences and their relation to lung cancer.

Eligibility:

* Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute.

Design:

* After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential.
* Approximately half a tablespoon of blood will be drawn.
* Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study
* Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.

Conditions

  • Carcinoma, Non-Small Cell Lung
  • Carcinoma, Small-Cell Lung

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Arun Rajan, M.D. · National Cancer Institute (NCI)

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-18
Completion
2018-04-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00923884 on ClinicalTrials.gov